Jan 23, 2026 04:13AM Tyra Biosciences (TYRA) PT Raised to $42 at Piper Sandler, Reiterate Top Pick

Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note

Dec 16, 2025 06:20AM Tyra Biosciences (TYRA) PT Raised to $37 at Wedbush, Adds to BIL

Dec 4, 2025 06:58AM Goldman Sachs Starts Tyra Biosciences (TYRA) at Early-Stage Biotech

Nov 5, 2025 04:38PM Tyra Biosciences, Inc. (TYRA) Reports In-Line Q3 EPS

Sep 10, 2025 08:19AM Tyra Biosciences (TYRA) PT Raised to $36 at Oppenheimer

Aug 14, 2025 04:07PM Tyra Biosciences, Inc. (TYRA) Tops Q2 EPS by 6c

Jul 1, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)

May 21, 2025 06:24AM Piper Sandler Assumes Tyra Biosciences (TYRA) at Overweight

May 8, 2025 07:58PM Tyra Biosciences, Inc. (TYRA) Tops Q1 EPS by 1c

Mar 31, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)

Feb 18, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)

Jan 29, 2025 04:06PM Tyra Biosciences (TYRA) Appoints Adele Gulfo to its Board

Jan 10, 2025 08:06AM Tyra Biosciences (TYRA) Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer

Jan 7, 2025 06:20AM UBS Starts Tyra Biosciences (TYRA) at Buy

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Nov 11, 2024 07:24AM Tyra Biosciences (TYRA) PT Lowered to $30 at H.C. Wainwright

Nov 7, 2024 04:22PM Tyra Biosciences, Inc. (TYRA) Misses Q3 EPS by 1c

Oct 28, 2024 10:42AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA)

Oct 28, 2024 07:00AM Tyra Biosciences (TYRA) Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia

Oct 28, 2024 06:39AM Tyra Biosciences (TYRA) PT Raised to $32 at H.C. Wainwright

Oct 25, 2024 07:12AM TD Cowen Reiterates Buy Rating on Tyra Biosciences (TYRA)

Oct 18, 2024 06:11AM BofA Securities Upgrades Tyra Biosciences (TYRA) to Buy

Oct 11, 2024 09:09AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA)

Oct 11, 2024 08:03AM Tyra Biosciences (TYRA) Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR

Oct 7, 2024 06:33AM Tyra Biosciences (TYRA) PT Raised to $30 at H.C. Wainwright

Oct 3, 2024 06:08AM Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA)

Sep 19, 2024 07:31AM Tyra Biosciences (TYRA) PT Raised to $33 at Oppenheimer

Sep 10, 2024 04:05PM Tyra Biosciences (TYRA) Appoints Doug Warner as Chief Medical Officer

Aug 15, 2024 04:40AM Piper Sandler Starts Tyra Biosciences (TYRA) at Overweight

Aug 8, 2024 06:37AM Tyra Biosciences (TYRA) PT Raised to $25 at H.C. Wainwright

Jul 8, 2024 11:31AM TD Cowen Reiterates Buy Rating on Tyra Biosciences (TYRA)

Jul 3, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)

Jul 2, 2024 04:05PM Tyra Biosciences (TYRA) Announces Preclinical Proof-of-Concept Results with TYRA-300